6VUA
X-ray structure of human CD38 catalytic domain with 2'-Cl-araNAD+
6VUA の概要
| エントリーDOI | 10.2210/pdb6vua/pdb |
| 分子名称 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{R},4~{R})-4-chloranyl-3-oxidanyl-oxolan-2-yl]methyl hydrogen phosphate, POTASSIUM ION, ... (8 entities in total) |
| 機能のキーワード | inhibitor, cd38, hydrolase |
| 由来する生物種 | Homo sapiens (Human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 61954.43 |
| 構造登録者 | Dai, Z.,Zhang, X.N.,Nasertorabi, F.,Han, G.W.,Stevens, R.C.,Zhang, Y. (登録日: 2020-02-14, 公開日: 2020-06-03, 最終更新日: 2024-10-23) |
| 主引用文献 | Dai, Z.,Zhang, X.N.,Nasertorabi, F.,Cheng, Q.,Li, J.,Katz, B.B.,Smbatyan, G.,Pei, H.,Louie, S.G.,Lenz, H.J.,Stevens, R.C.,Zhang, Y. Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases. Sci Adv, 6:eaba6752-eaba6752, 2020 Cited by PubMed Abstract: Most of the current antibody-drug conjugates (ADCs) in clinic are heterogeneous mixtures. To produce homogeneous ADCs, established procedures often require multiple steps or long reaction times. The introduced mutations or foreign sequences may cause high immunogenicity. Here, we explore a new concept of transforming CD38 enzymatic activity into a facile approach for generating site-specific ADCs. This was achieved through coupling bifunctional antibody-CD38 fusion proteins with designer dinucleotide-based covalent inhibitors with stably attached payloads. The resulting adenosine diphosphate-ribosyl cyclase-enabled ADC (ARC-ADC) with a drug-to-antibody ratio of 2 could be rapidly generated through single-step conjugation. The generated ARC-ADC targeting human epidermal growth factor receptor 2 (HER2) displays excellent stability and potency against HER2-positive breast cancer both in vitro and in vivo. This proof-of-concept study demonstrates a new strategy for production of site-specific ADCs. It may provide a general approach for the development of a novel class of ADCs with potentially enhanced properties. PubMed: 32537509DOI: 10.1126/sciadv.aba6752 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.5 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






